TY  - CHAP
M1  - Book, Section
TI  - Chapter 226. Aminoquinolines
A1  - McClain, Susannah E.
A1  - LaDuca, Jeffrey R.
A1  - Gaspari, Anthony A.
A2  - Goldsmith, Lowell A.
A2  - Katz, Stephen I.
A2  - Gilchrest, Barbara A.
A2  - Paller, Amy S.
A2  - Leffell, David J.
A2  - Wolff, Klaus
Y1  - 2012
N1  - 
T2  - Fitzpatrick's Dermatology in General Medicine, 8e
AB  - |PrintAminoquinolines  at  a  GlanceAminoquinolines  have  been  used  in  clinical  medicine  for  more  than  a  century,  initially  as  antimalarial  compounds.Multiple  mechanisms  of  action,  particularly  impaired  lysosomal  acidification  by  antigen  presenting  cells,  inhibition  of  natural  killer  and  T-cell  activation,  and  inhibition  of  lipid  mediators  of  inflammation.Propensity  for  melanin  pigment,  absorb  ultraviolet  light,  and  exhibit  photoprotective  properties  against  ultraviolet-mediated  injury  of  the  skin.Aminoquinolines  used  to  treat  dermatologic  conditions  include  hydroxychloroquine,  chloroquine,  and  quinacrine.Hydroxychloroquine  is  the  most  commonly  used  aminoquinoline  for  skin  conditions  and  is  well  studied  for  chronic  cutaneous  lupus  erythematosus.Other  aminoquinoline-responsive  conditions:  porphyria  cutanea  tarda,  polymorphous  light  eruption,  cutaneous  sarcoidosis,  dermatomyositis,  and  other  conditions.Laboratory  monitoring  is  mandatory  during  aminoquinoline  therapy  to  detect  hematologic  abnormalities  (hemolysis  and  drug-induced  cytopenias),  liver  injury,  and  ophthalmologic  toxicity  (retinopathy).Children  are  especially  susceptible  to  aminoquinoline  toxicities,  and  lower  doses  must  be  used  than  in  adults.Drug  interactions  are  possible,  and  cigarette  smoking  decreases  efficacy  of  aminoquinolines  by  inducing  cytochrome  P450  enzymes.  
SN  - 
PB  - The McGraw-Hill Companies
CY  - New York, NY
Y2  - 2024/04/20
UR  - accessmedicine.mhmedical.com/content.aspx?aid=56099042
ER  -